Twist Bioscience (TWST) and Ginkgo Bioworks (DNA) have renegotiated a previous contract signed in 2022 to provide Twist with key licenses to long DNA technology and assets, the companies said Thursday.
Under the revised $15 million agreement, which runs for three years, Ginkgo will continue to be a valued customer of Twist and will prepay annually for orders of Twist's DNA products. It will also receive preferential pricing for DNA products with no required minimum purchase volume.
Twist will receive licenses and assignments for certain long DNA and other technology as well as related reagents to complement its existing DNA synthesis portfolio of products, and Ginkgo will retain the rights to practice the intellectual property transferred to Twist, the announcement states.
Price: 32.16, Change: -0.63, Percent Change: -1.91
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。